The Difference of Thyroid Cancer in Hyperactive Adenoma and Hyperthyroidism in Endemic Areas
PDF
Cite
Share
Request
Original Article
P: 319-324
September 2019

The Difference of Thyroid Cancer in Hyperactive Adenoma and Hyperthyroidism in Endemic Areas

Med Bull Haseki 2019;57(3):319-324
1. Sağlık Bilimleri Üniversitesi, Haseki Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, İstanbul, Türkiye
2. Memorial Hizmet Hastanesi, Aile Hekimliği Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 01.07.2019
Accepted Date: 28.08.2019
Publish Date: 20.09.2019
PDF
Cite
Share
Request

ABSTRACT

Aim:

In recent years, dramatic changes in treatment approaches and conflicting publications on thyroid cancer have been reported from endemic regions. The probability of cancer has increased in endemic areas especially in the presence of hyperactive adenoma (HA) and/or hyperthyroidism (HT). It has been suggested that subclinical and clinical hyperthyroidism increase the risk of several solid malignancies while hypothyroidism may reduce aggressiveness or delay the onset of cancer.

Methods:

In this retrospective study, a total of 162 patients, who were operated for HA and/or HT between 2004 and 2009 in a training and research hospital, were compared with 332 controls who were operated for other thyroid diseases. The study group consisted of 33 patients with HA alone, 89 patients with HT alone, and 40 patients with both. Statistical analysis was performed with NCSS 2007 package program.

Results:

The cancer rate was 8.7% in patients with HA and 9.5% in those with HT. There was no statistically significant difference between patients with HA or HT and controls. Three of 13 patients with cancer in the study group and 13 of 26 in the control group had microinvasive papillary cancer. LDH and ALP values in the study group were statistically lower than in the control group. When compared with the control group, the diameter of dominant nodule was statistically significantly larger in the whole study group (p=0.008), in patients with HA (p=0.003) and those with HT (p=0.021).

Conclusion:

Cancer risk does not decrease in the presence of HA and/or HT.

References

1Hyun MK, Kim JH, Kwon JW. Incidence of thyroid cancer and medical cost among patients with newly diagnosed thyroid nodules in Korea: A retrospective cohort study using nationwide data. J Cancer ResTher 2019;15:676-80.
2Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol 2015;27:15-20.
3Kuo EJ, Wu JX, Li N, et al. Nonoperative management of differentiated thyroid cancer in California: a population-level analysis of 29,978 patients. EndocrPract 2017;23:1262-9.
4Bombil I, Bentley A, Kruger D, et al. Incidental cancer in multinodular goitre post thyroidectomy. S Afr J Surg 2014;52:5-9.
5Fama F, Sindoni A, Cicciu M, et al. Preoperatively undiagnosed papillary thyroid carcinoma in patients thyroidectomized for benign multinodular goiter. Arch Endocrinol Metab 2018; 62:139-48.
6Rieger R, Pipml W, Money S, et al. Hyperthyroidism and concurrent thyroid malignancies. Surgery 1989;106:6-10.
7Sharma SD, Kumar G, Guner K, et al. Hyperthyroidism in patients with thyroid cancer. Ear Nose Throat J 2016;95:236-9.
8Zanella E, Rulli F, Muzi M, et al. Prevalance of thyroid cancer in hyperthyroid patients treated by surgery. World J Surg 1998;22:473-8.
9David E, Rosen IB, Bain J, et al. Management of hot thyroid nodule. Am J Surg 1995;170:481-3.
10Taşkesen F, Uslukaya Ö, Oğuz A, et al. Hipertiroidizm ile tiroid kanseri birlikteliği. Dicle Med J 2014;41:364-7.
11Kaliszewski K, Wojtczak B, Strutynska-Karpinska M, et al. Incidental and non-incidental thyroid microcarcinoma. Oncol Lett 2016;12:734-40.
12LiVolsi VA, Baloch ZW. The Pathology of Hyperthyroidism. Front Endocrinol (Lausanne) 2018;9:737.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House